Nucleate Singapore

🔬The Nucleate Artery: Drug delivery using bacteria, and new ways to remove harmful fat build ups 📰 This month’s issue is packed with biotech breakthroughs that push the boundaries of how we think about drug delivery, joint aging, brain health, and metabolic disease. 🦠 Nose-to-Brain Drug Delivery Using Engineered Bacteria: NUS scientists engineered Lactobacillus plantarum to secrete appetite-suppressing hormones directly into the brain, showing real potential for treating obesity and other neurological diseases. 🧓 Protecting Aging Joints from Arthritis: Researchers at A*STAR uncovered a key mechanism behind cartilage breakdown and identified new therapeutic targets to slow joint degeneration. 🧠 Clearing Brain Fat to Fight Alzheimer’s: NTU scientists found that reducing lipid buildup in brain immune cells helps them better clear harmful plaques. 🎯 Boosting Immunotherapy with Nanomaterials: Researchers at NTU developed multifunctional palladium-iron nanosheets that supercharge the cancer-immunity cycle and improve T-cell activity in tumors. ❤️ Liver-Brain-Heart Crosstalk in Cardiovascular Disease: NUS researchers discovered that targeting liver-specific SREBP2 significantly reduces cholesterol and atherosclerosis risk, opening up opportunities for inter-organ therapies for heart disease. 🗞️ Wondering what went down in our biohack event, and want to learn about opportunities and events happening in the intersection of AI and drug discovery? check out our event takeaways this month! Read the full issue here 👉 https://lnkd.in/gzZgvgAU Newsletter team: Jiaqi Liang, Senuri De Silva, Damien Chua, Devika Menon Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Shruti Sridhar, Gloria Chan, Isha Karnik, John Joson Ng, Panida Cen, Jashan Singh, Roshni Gupta, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Diya Srivastava, Dijin Zhang, Janelle Low #NucleateSingapore #NucleateArtery 

🧬 Nucleate Ignite Workshop 2: Navigating Clinical Development The second session of the Nucleate Ignite: Biotherapeutic Development Workshop brought participants face-to-face with the intricate process of advancing a therapeutic from target identification through to late-stage clinical trials, with a focus on oncology. Led by Dr. Veronica Diermayr PhD, Asset Development Leader at the Experimental Drug Development Centre (EDDC), the session explored how to build a strategic and comprehensive Clinical Development Plan — from defining the unmet medical need and establishing a Target Product Profile (TPP) to navigating regulatory interactions and designing trials across all phases. Participants gained valuable insights into approaches for biomarker identification, comparisons between traditional and Bayesian trial designs, the rationale behind dose optimization strategies, and regulatory nuances across the US and Singapore. Dr. Diermayr also elaborated on Project Optimus and emphasized the importance of early engagement through Pre-IND and Interact meetings. Real-world examples from antibody-drug conjugate (ADC) programs at EDDC illustrated how complex assets are advanced through global trials, with detailed discussion on risk management strategies, statistical planning, and the construction of a robust trial master file to support regulatory submissions. The evening concluded with an engaging Q&A session with Dr. Diermayr, and included a networking dinner where participants had the opportunity to connect with her and continue meaningful conversations with fellow attendees. We’re excited to see the workshop series come to a close with the final session happening this Tuesday. Stay tuned as we wrap up this journey of translating science into real-world impact! P&E team: Gloria Chan, Panida Cen, Roshni Gupta Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Jiaqi Liang, Damien Chua, Isha Karnik, John Joson Ng, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Senuri De Silva, Diya Srivastava, Dijin Zhang, Devika Menon, Janelle Low #NucleateIgnite #Biotherapeutics #DrugDevelopment #ClinicalTrials #RegulatoryStrategy #BiotechInnovation #TranslationalScience #LifeSciencesLeadership #FromBenchToBedside #NucleateSingapore

A strong IP strategy is fundamental to success in today’s fast-paced biotech landscape. Following his conversation with John Joson Ng for Nucleate Singapore Pulse, we speak to Adam Gregory about crafting effective IP strategies for biotech ventures, avoiding common pitfalls, and adapting to growth and emerging technologies: https://hubs.la/Q03gK8Dz0 #Biotech #MewburnLifeSciences #SingaporeBiotech #IP #LifeSciences #IPStrategy

🚀  Nucleate Ignite Biotherapeutic Development Workshop – Day 1 Day 1 of the Nucleate Ignite Biotherapeutic Development Workshop opened with an insightful session by Dipti Thakkar, who brought deep industry expertise to unpack the journey from scientific discovery to an approved therapeutic. Participants were introduced to the fundamentals of drug development — from pre-discovery and candidate selection, to regulatory strategy and clinical trial design. The session covered how to approach IND filings, what regulators prioritize at different stages, and how to think strategically about data generation and timelines. Attendees also explored the importance of defining a strong Target Product Profile (TPP), the balance between pharmacokinetics (PK) and pharmacodynamics (PD), and how different stakeholders — regulators, investors, and pharma — view risk, novelty, and value. The day included an engaging networking dinner, where participants continued the conversation sharing ideas, discussing challenges in translational research, and getting their questions answered directly by the speaker and peers in an informal setting. And we’re only getting started! Day 2 features hands-on sessions and deeper dives with expert speakers. We look forward to growing this vibrant translational science community together! P&E team: Gloria Chan, Panida Cen, Roshni Gupta Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Jiaqi Liang, Damien Chua, Isha Karnik, John Joson Ng, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Senuri De Silva, Diya Srivastava, Dijin Zhang, Devika Menon, Janelle Low #NucleateIgnite #BiotechInnovation #ClinicalTrials #DrugDevelopment #PharmaStrategy #TranslationalScience #LifeScienceLeadership #FromBenchToBedside #BiotechStartups #MedTech #NucleateSingapore

🎙 Nucleate Singapore Pulse 🚀This month, Nucleate sat down with Dr. Ivan Horak, Founder and CEO of Tikva Allocell Pte Ltd., a late preclinical stage biotech company headquartered in Singapore. Tikva Allocell develops off-the-shelf CAR-T therapy using second-generation allogeneic T cells from EBV-positive individuals to target solid tumors like gastric, prostate, and triple-negative breast cancers. 🎧 In this episode, Dr. Horak discusses his extensive experience and insights through his professional journey in the biotech and pharmaceutical industries as a clinician and researcher. He delves into the complexities of developing effective cancer therapies, highlighting challenges posed by cancer’s heterogeneity and resistance mechanisms. He emphasizes the importance of targeting specific molecular pathways and biomarkers to enhance treatment efficacy and explores how advancements in data analytics, biomarker discovery, and AI-driven platforms are revolutionizing drug development. Dr. Horak also underscores the critical role of collaboration between researchers, clinicians, and pharmaceutical companies in driving innovation and accelerating the development of transformative therapies. Listen and follow us on Spotify 👉https://lnkd.in/gqCmVFM2  and Apple Podcasts 👉https://lnkd.in/gn3x-ihk Show notes and transcripts 👉https://lnkd.in/grpAx5yQ Podcast team: John Joson Ng, Hana Maldivita Tambrin, PhD, Dillon Chew, and Aakash Kumar Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Jiaqi Liang, Damien Chua, Gloria Chan, Isha Karnik, Senuri De Silva, Panida Cen, Roshni Gupta, Diya Srivastava, Dijin Zhang, Devika Menon, Janelle Low #Biotech #Therapeutics #Cancer #Oncology #R&D #Nucleate #Podcast

🔬 The Nucleate Artery: Looking back at half a year of breakthroughs! 📰  ICYMI, we're reflecting on the most exciting biotech innovations we've covered over the past six months! Check out the cutting-edge research that’s shaping the future of healthcare and life sciences in Singapore. 🧬 Want to stay youthful? Discover how Duke-NUS scientists are targeting IL-11 and DEAF1 pathways to reverse aging and muscle loss. 🎗 New Frontiers in Cancer Therapy: From gold nanoparticles to magnetic pulses, learn how Singaporean researchers are improving cancer drug delivery and minimising side effects. 🤖 Bio-Inspired Engineering: Did you miss our issues on robots with a 'sense' of touch and batteries made from flies? ⚕️ Metabolic Health: Check out our coverage of diabetic wound-healing nanotech and multi-target glucagon blockade drugs! We’ve picked our favourites - do *you* have a favourite theme or Digestible? Let us know in the comments below! 🗞️ Stay updated with the latest news on the biggest biotech industry updates, new collaborations, and can’t-miss conferences. Read the full issue here 👉https://lnkd.in/gVBCwU2c Newsletter team: Jiaqi Liang, Senuri De Silva, Damien Chua, Devika Menon Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Shruti Sridhar, Gloria Chan, Isha Karnik, John Joson Ng, Panida Cen, Jashan Singh, Roshni Gupta, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Diya Srivastava, Dijin Zhang, Janelle Low #NucleateSingapore #NucleateArtery 

🚀 Nucleate Ignite: Biotherapeutic Development Workshop – Last Chance to Apply! Applications for our closed-door Biotherapeutic Development workshop series close on 3rd March—this is your final opportunity to apply! Gain exclusive insights from leading industry experts on IND applications, clinical trial planning, and intellectual property strategy. This highly curated session will also provide a chance to network with biotech leaders and connect over food and refreshments after each session. Workshop Series Schedule: 📅 1 April – The IND Application and Target Product Profile 1. Dipti Thakkar (VP, Target Biology & Pharmacology, Hummingbird Bioscience) 2. Carlo Polo (Senior Director, Regulatory Science, Hummingbird Bioscience) 📅 8 April – The Clinical Development Plan and Considerations for Early-Stage Clinical Trials 1. Veronica Diermayr (Director, Asset Lead, Experimental Drug Development Centre) 📅 15 April – Intellectual Property Strategy for Biotherapeutic Companies 1. Adam Gregory (Partner, Patent Attorney, Mewburn Ellis) 2. Thomas Driver (Associate, Patent Attorney, Mewburn Ellis) ⏰ Time: 6:30 - 9:30 PM 📍 Venue: Details will be shared with confirmed participants 🔗 Submit your application before 3rd March: https://lnkd.in/gA9yJCrN A special thanks to Sartorius for supporting this workshop. Don’t miss this opportunity to learn from industry leaders, expand your professional network, and refine your strategy for biotherapeutic success. Apply now before it’s too late! #NucleateIgnite #Biotech #DrugDevelopment #ClinicalTrials #IntellectualProperty #Innovation #NucleateSingapore #Entrepreneurship Ying Tong Yeo Jessie Wong Ling Ai Samantha Wong, PhD Ivan Seah, MBBS/MBA/MPH Gloria Chan Isha Karnik John Joson Ng Panida Cen Roshni Gupta Hana Maldivita Tambrin, PhD Dillon Chew Aakash Kumar Diya Srivastava Dijin Zhang Jiaqi Liang Senuri De Silva Damien Chua Devika Menon Janelle Low

🎙 Nucleate Singapore Pulse 🚀 This month, Nucleate sat down with Dr. Joshua Weiyuan Wang Ph.D., Founding CEO and President of VerImmune Inc., a biotech company pioneering cancer therapy innovations with its proprietary Virus-Inspired Particle (ViP™) platform, which harnesses the body’s pre-existing immune memory to combat cancer. 🎧 In this episode, Dr. Wang shares his biotech entrepreneurship journey, from launching two startups to how a casual conversation with tech bros sparked the development of Anti-Tumor Immune Redirection (AIR-ViP™). He also dives into the critical role of Chemistry, Manufacturing & Controls (CMC) in drug development, VerImmune’s strategic partnerships with A*STAR and NSG Biolabs, and offers key advice for aspiring biotech founders navigating the challenges of the industry. Listen and follow us on Spotify 👉 https://lnkd.in/gP497DCd and Apple Podcasts 👉https://lnkd.in/gZcTV5fU Show notes and transcripts 👉 https://lnkd.in/gGMDCywT Podcast team: John Joson Ng, Hana Maldivita Tambrin, PhD, Dillon Chew, and Aakash Kumar Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Jiaqi Liang, Damien Chua, Gloria Chan, Isha Karnik, Senuri De Silva, Panida Cen, Diya Srivastava, Dijin Zhang, Devika Menon, Janelle Low #Biotech #Therapeutics #Cancer #Oncology #R&D #Nucleate #Podcast

🔬 The Nucleate Artery: It’s cancer and immunotherapy month! 📰 In this month's edition, we're excited to bring you cutting-edge Digestibles showcasing innovative research from Singapore’s leading institutes: 🔷Shaping Cancer Therapy with Gold: Discover how National University of Singapore researchers are revolutionizing cancer treatment by identifying the most effective nanoparticle shapes for targeting tumors in real-world conditions. 🎯Enhancing Immunotherapy: Learn about Institute of Molecular and Cell Biology (IMCB)'s discovery of an enzyme-protein interaction as a novel target to boost immunotherapy effectiveness. 💉Next-Gen Cancer Vaccines: Researchers at @SIgN developed artificial cell membrane polymersomes for delivering cancer vaccines, showing promising results in melanoma models. 🗺️Mapping Gastric Cancer: See how NUS researchers are using spatial transcriptomics to unveil distinct tumor subgroups, paving the way for personalized treatments. 🦠T-Cell Power Unleashed: Scientists at Duke-NUS Medical School proved that T-cells can independently fight viral infections without neutralizing antibodies, offering a new way to assess vaccine efficacy. 🗞️Stay updated with the latest news on Singapore's thriving biotech ecosystem, including the launch of Medtech Catapult, a $38M initiative aimed at supporting medtech companies, and exciting international collaborations in microbiome research and cancer diagnostics. Learn more in our Industry Spotlight! 📆 Don't miss this month's packed calendar of events! From the Mental Health & Wellness AI Tech Summit to specialized workshops on AI in drug discovery, explore numerous opportunities to connect with industry leaders and enhance your expertise. Plus, our Nucleate Ignite Biotherapeutic Development Workshop is back! Spots are limited for the event, so make sure to sign up before 4th March to secure your place. Sign up here: https://lnkd.in/gpgDBxDs Read the full issue here!  👉https://lnkd.in/gDJ6JXwQ Newsletter team: Jiaqi Liang, Senuri De Silva, Damien Chua, Devika Menon Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Shruti Sridhar, Gloria Chan, Isha Karnik, John Joson Ng, Panida Cen, Jashan Singh, Roshni Gupta, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Diya Srivastava, Dijin Zhang, Janelle Low #NucleateSingapore #NucleateArtery 

🚀 Nucleate Ignite: Biotherapeutic Development Workshop – Applications Now Open! Are you developing an innovative biotherapeutic and seeking guidance on how to advance it to clinical trials? Join Nucleate Singapore for a closed-door workshop series featuring leading experts in drug development, where selected participants will gain critical insights into IND applications, clinical trial strategy, and intellectual property considerations. This exclusive session offers a unique opportunity to engage with industry leaders, expand your network, and gain firsthand knowledge on the biotherapeutic development process. Food and refreshments will be provided to facilitate meaningful discussions and networking. Workshop Series Schedule: 📅 1 April – The IND Application and Target Product Profile Dipti Thakkar (VP, Target Biology & Pharmacology, Hummingbird Bioscience) CARLO POLO (Senior Director, Regulatory Science, Hummingbird Bioscience) 📅 8 April – The Clinical Development Plan and Considerations for Early Stage Clinical Trials Veronica Diermayr PhD Diermayr (Director, Asset Lead, Experimental Drug Development Centre) 📅 15 April – Intellectual Property Strategy for Biotherapeutic Companies Adam Gregory (Partner, Patent Attorney, Mewburn Ellis) Thomas Driver (Associate, Patent Attorney, Mewburn Ellis) ⏰ Time: 6:30 - 9:30 PM 📍 Venue: Details will be shared with confirmed participants 🔗 Submit your application now: https://lnkd.in/gA9yJCrN A special thanks to Sartorius for supporting this initiative. Don’t miss this opportunity to gain exclusive insights, connect with biotech leaders, and refine your strategy for biotherapeutic success. #NucleateIgnite #Biotech #DrugDevelopment #IntellectualProperty #Innovation #NucleateSingapore #Entrepreneurship Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Gloria Chan, Panida Cen, Roshni Gupta, John Joson Ng, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Isha Karnik, Diya Srivastava, Dijin Zhang, Jiaqi Liang, Senuri De Silva, Damien Chua, Devika Menon, Janelle Low